timberwolf7 Friday, 10/30/20 07:45:49 PM Re: None Post # of 2551 there is this article on results published back in Feb 2019.. I have to keep reminding myself that this is just something that is designed to make something else 'more achievable/effective'... ie, if you use it, does the 'standard of care' currently in use work 'better' than it does... Unless this trial interim readout shows the standard of care currently in use is just as 'good' or that the pre-conditioning adds no value... But the prior results appear to say, pre-conditioning makes the 'standard of care' better, more effective... but at the same time, even if approved, I don't see the share price doing a heck of a lot more than $20 ($220 Million market cap) to sum it up? Does Iomabb make the standard of care better or not?? Based on whats been reported, sounds like it.. https://www.onclive.com/view/iomabb-shows-promise-as-novel-conditioning-for-hsct-in-aml February 24, 2019